The FDA’s new announcement, Flexible Requirements for Cell and Gene Therapies to Advance Innovation , signals a notable shift in how regulators are thinking about manufacturing controls during early- and mid-stage development of cell and gene therapies (CGTs). The intent is clear: reduce unnecessary friction, lower barriers to clinical entry, and accelerate innovation for therapies often targeting serious or life-threatening diseases.  At the heart of the guidance are two sta

The FDA’s latest innovation signals reveal how regulatory systems are evolving—and what FDA regulatory innovation may increasingly require from industry.

TL;DR: FDA’s new Commissioner’s National Priority Voucher (CNPV) program  accelerates reviews to ~1–2 months for products that advance U.S. national priorities: big-burden diseases, public-health crises, affordability, and on-shored manufacturing. If you’re heading into this pathway, success hinges on early CMC and labeling completeness, disciplined traceability, and an operating model built for rapid, team-based review.   What’s inside the program  Why it exists:  Speed acce